Postgraduate Course in Cardiometabolic Medicine 2024
-
City
London, UK
Type of event
on site
Invitation
Now Day Tickets Available!
Dear Colleagues
It is a pleasure to announce a truly innovative Postgraduate Course in Cardiometabolic Medicine, a timely and highly acclaimed educational programme conceived by Zurich Heart House – London Heart House, King’s College, and Royal Brompton & Harefield Hospitals, which will address an unmet educational need.
Cardiometabolic disorders represent a cluster of interrelated risk factors, primarily dyslipidemia, hypertension, elevated fasting blood glucose, obesity and non-alcoholic steatohepatitis. A combination of several of these risk factors massively increases the incidence and mortality of coronary heart disease and stroke. The strong association between metabolic disorders and cardiovascular health delivers a compelling reason to improve awareness of this cluster by identifying the risk factors and inducing targeted interventions.
The Postgraduate Course in Cardiometabolic Medicine consists of a four-day programme. State of the art lectures alternate with a great variety of interactive sessions, including workshops, rapid fire sessions and hands-on imaging sessions.
The course offers a unique opportunity to become one of the first experts in the seminal area of cardiometabolic medicine. We are looking forward to receiving your application and meeting you in London.
Sincerely,
Andrew Krentz
Thomas F. Lüscher
Naveed Sattar
John Deanfield
Mahmoud Barbir
Michael Papadakis
Scientific Programme
Tuesday, April 30th, 2024 (UK time)
Venue: The Royal Society of Medicine
| 08:00 | REGISTRATION AND COFFEE | ||
|---|---|---|
| 08:30 | Welcome Session | ||
| 08:30 | Welcome by the course directors | |
| 08:45 | Course concept and structure | |
| 09:00 | Session 1: Obesity I- Causes and mechanisms Chairs: John E. Deanfield & Michael Papadakis | ||
|---|---|---|
| 09:00 | Is obesity a disease? If so, how do we diagnose? | Francesco Rubino, London |
| 09:20 | The gut microbiome: a new risk factor for obesity and CVD | Thomas F. Lüscher, London |
| 09:40 | Obesity and inflammation | Marc Donath, Basel |
| 10:00 | What links adiposity to CVD? | Naveed Sattar, Glasgow |
| 10:20 | Panel discussion | |
| 11:00 | COFFEE | ||
| 11:30 | Session 2: Obesity II – Management Chairs: Naveed Sattar & Thomas F. Lüscher | ||
|---|---|---|
| 11:30 | Bariatric surgery: is there still a role? | Barbara McGowan, London |
| 11:50 | Behavioural management: Nutrition | Michael Lean, Glasgow |
| 12:10 | Behavioural management: Exercise & sports – the ESC guidelines 2020 and beyond | Michael Papadakis, London |
| 12:30 | Medical management of obesity: GLP-1/GIP agonists | John E. Deanfield, London |
| 12:50 | Panel discussion | |
| 13:30 | LUNCH BREAK and INTERACTIVE INDUSTRY EXHIBITION | ||
| 14:30 | Session 3: ASCVD Assessment I Chairs: Mahmoud Barbir & Thomas F. Lüscher | ||
|---|---|---|
| 14:30 | Inflammation and plaque formation | Christian Weber, Munich |
| 14:50 | LDL-C and cardiovascular disease: Why is lower better? | Lale Tokgozolu, Ankara |
| 15:10 | Cardiovascular risk assessment: the ESC SCORE/SCORE2-OP | Frank Visseren, Utrecht |
| 15:30 | Lifetime risk: CVD prevention - personal and national strategy | John E. Deanfield, London |
| 15:50 | Panel discussion | |
| 16:30 | COFFEE BREAK | ||
| 17:00 | Case-based interactive seminars | ||
| How to assess adiposity: Clinical, MRI and beyond | Geltrude Mingrone, London | |
| How to manage obesity | Barbara McGowan, London | |
| 18:00 | End of day 1 | ||
Wednesday, May 1st, 2024
| 09:00 | Session 4: ASCVD Assessment II Chairs:John Chapman & Christian Heiss | ||
|---|---|---|
| 09:00 | Multimodality imaging to assess ASCVD | Chrsitoph Gräni, Bern |
| 09:20 | CT-based coronary imaging for risk prediction | Charalambos Antoniades, Oxford |
| 09:40 | Novel lipoproteins: Lipoprotein(a) | Francois Mach, Geneva |
| 10:00 | Are triglycerides a cardiovascular risk factor? | Børge Nordestgaard, Copenhagen |
| 10:20 | Panel discussion | |
| 11:00 | COFFEE BREAK | ||
| 11:30 | Session 5: ASCVD - Management Chairs: Jürg H. Beer & Francois Mach | ||
|---|---|---|
| 11:30 | Secondary hypertension: an underrecognized condition | Tomasz Guzik, Edinburgh |
| 11:50 | Unsaturated fatty acids and CV risk reduction | John Chapman, Paris |
| 12:10 | Personalized LDL-C management: From pills to nucleic acids | Kausik Ray, London |
| 12:30 | Arterial hypertension: from drugs to devices | Vikas Kapil, London |
| 12:50 | Panel discussion | |
| 13:30 | LUNCH BREAK and INTERACTIVE INDUSTRY EXHIBITION | ||
| 14:30 | Hands-on seminars | ||
| Practical lipid apheresis | Mahmoud Barbir, London / Jo Senior, Harefield / Alison Pottle, Harefield / Stefan Bornstein, Dresden | |
| Assessing vascular structure and function - practical demonstrations | Christian Heiss, Guildford | |
| 16:30 | COFFEE BREAK | ||
| 17:00 | Session 6 ASCVD: Platelets and coagulation Chairs:Thomas F. Lüscher & Shouvik Haldar | ||
|---|---|---|
| 17:00 | Intravascular thrombus formation: platelets and intrinsic/extrinsic system | Jürg H. Beer, Baden |
| 17:20 | Platelet inhibition: DAPT or SAPT? (the 2023 ESC guidelines on ACS) | Robert Byrne, Dublin |
| 17:40 | Novel oral anticoagulants in VTE and AF: the ESC Guidelines and beyond | A. John Camm, London |
| 18:00 | Panel discussion | |
| 18:15 | NETWORKING RECEPTION | ||
Thursday, May 2nd, 2024
| 09:00 | Session 7: Diabetes mellitus (DM) Chairs: Andrew Krentz & Stephan Jacob | ||
|---|---|---|
| 09:00 | Pathogenesis of Type 2 DM | Marc Donath, Basel |
| 09:20 | Diabetes Type 2 and CVD beyond glucocentricity | Stephan Jacob, Villingen |
| 09:40 | Management of CVD risk in type 2 diabetes – the 2023 ESC Diabetes guidelines | Dirk Müller-Wieland, Aachen |
| 10:00 | Panel discussion | |
| 10:30 | COFFEE BREAK | ||
| 11:00 | Session 8: Nephrology - Chronic kidney disease (CKD) – Causes & Mechanisms Chairs: Joao Pedro Ferreira & Andrew Krnetz | ||
|---|---|---|
| 11:00 | Causes and clinical presentation of CKD | Britta George. Zurich |
| 11:20 | CKD and cardiovascular risk | Thimoteus Speer, Frankfurt |
| 11:40 | Albuminuria, eGFR slopes and outcomes: impact of pharmacotherapy | David Wheeler, London |
| 12:00 | Panel discussion | |
| 12:30 | Industry Sponsored Symposium: Challenging the Status Quo in Cardiorenal Management This is a promotional symposium sponsored and organised by AstraZeneca, intended for GB HCPs only | |
| 13:15 | LUNCH BREAK and INTERACTIVE INDUSTRY EXHIBITION | ||
| 14:00 | Session 9: Nephrology - Chronic kidney disease (CKD) - Management Chairs: Thimoteus Speer & Britta George | ||
|---|---|---|
| 14:00 | SGLT2i and GLP1-RA bin CKD and DKD – the 4 pillar approach | Christoph Wanner, Würzburg (remote) |
| 14:20 | Non-steroidal MR antagonists | Bertram Pitt, An Arbor (remote) |
| 14:40 | Management of hyperkalemia in CKD and HFrEF | Joao Pedro Ferreira, Porto |
| 15:00 | Panel discussion | |
| 15:30 | COFFEE BREAK | ||
| 16:00 | Case-based interactive seminars | ||
| Managing type 2 diabetes and CVD risk | Stephan Jacob, Villingen | |
| Managing patients with CKD | Timo Speer, Frankfurt | |
| 17:00 | End of day 3 | ||
Friday, May 3rd, 2024
| 09:00 | Session 10: Metabolic dysfunction-associated steatotic liver disease (MASLD) and Endocrinology Chairs: Andrew Krentz & Kamlesh Khunti | ||
|---|---|---|
| 09:00 | Screening and diagnosis of MASLD | Philip Newsome, Birmingham |
| 09:20 | Extrahepatic cardiometabolic disease associations with MASLD | Kevin Moore, London |
| 09:40 | Management of MASLD | William Alazawi, London |
| 10:00 | Cardiovascular risk in endocrine disease | Adrian Heald, Manchester |
| 10:20 | Sex hormones | Andrew Krentz, London |
| 10:40 | Panel discussion | |
| 11:00 | COFFEE BREAK | ||
| 11:30 | Session 11: Amyloid heart disease Chairs: Rakesh Sharma & Eleanor Wicks | ||
|---|---|---|
| 11:30 | The spectrum of amyloid heart disease | Ashutosh Wechalekar, London |
| 11:50 | Diagnosis and management of cardiac amyloidosis | Roy S. Gardner, Glasgow |
| 12:10 | Panel discussion | |
| 12:30 | LUNCH BREAK and INTERACTIVE INDUSTRY EXHIBITION | ||
| 13:30 | Session 12: Heart failure Chairs: Roy Gardner & Rajdeep Khattar | ||
|---|---|---|
| 13:30 | Prevention of heart failure | Pardeep Jhund, Glasgow |
| 13:50 | The different forms of heart failure | Aigul Baltabaeva, London |
| 14:10 | Comorbidities of heart failure | Michele Senni, Bergamo |
| 14:30 | Iron deficienca nd heart failure | Paul Kalra, Portsmouth |
| 14:50 | Management of heart failure: the 2021 and 2023 ESC guidelines | Theresa McDonagh, London |
| 15:10 | Panel discussion | |
| 15:30 | COFFEE | ||
| 16:00 | Hands-on seminars | ||
| Diagnosing MASLD with FibroScan | Kevin Moore, London | |
| Diagnosing heart failure with echocardiography | Rajdeep Khattar, London | |
| 17:00 | End of day 4 | ||
The programme may be subject to change.
Industry Sponsored Symposium
Thursday, May 2nd, 2024
| 12:30 | Challenging the Status Quo in Cardiorenal Management | |
| This is a promotional symposium sponsored and organised by AstraZeneca, intended for GB HCPs only. | ||
| Speakers: | Professor Derek Connolly, BSc[Hons] MB ChB[Edin] PhD[Cantab] DSc[Hon] FRCP FRCPE FESC, Consultant Cardiologist, Birmingham City & Sandwell Hospitals | |
| Dr Kate Bramham, Reader of Nephrology & Maternal Medicine and Honorary Consultant Nephrologist, King’s College London | ||
General Information
Registration
| Category | |
|---|---|
| Registration fees | |
| Regular fee | GBP 950 |
| Early registration fee (until March 1, 2024) | GBP 850 |
| Trainees/Residents, Research fellows, Nurses, Students <40 years (ID proof required)* | GPB 700 |
| Day Tickets | GPB 240 |
*For the reduced registration (Trainees/Residents, Research fellows, Nurses, Students <40 years) please send a copy of your ID to Ms. Christine Lohmann at christine.lohmann@zhh.ch
Registration will be confirmed upon receipt of payment.
Please note that UK banks may charge high fees for international bank transfers. We therefore recommend payment by credit card.
Modification & Cancellation
All modifications or cancellations must be notified in writing (by mail, fax or e-mail) to Zurich Heart House. For each modification requested by the participant, GBP 15 will be charged for administrative costs. In case of cancellation up to March 31st, 2024, deposits will be refunded less 35% for administrative costs. After this date, no refund will be possible.
Venue
The Royal Society of Medicine,
1 Wimpole St, Marylebone, London W1G 0AE, United Kingdom
Organisation
Zurich Heart House, Foundation for Cardiovascular Research
Dr. Ruth Amstein
Christine Lohmann
Hottingerstrasse 14, CH-8032 Zurich, Switzerland
Phone +41 (0) 44 250 40 95, Fax +41 (0) 44 250 40 90
Accreditation
The Postgraduate Course in Cardiometabolic Medicine has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 26 category 1 (external) CPD credit(s).
The Postgraduate Course in Cardiometabolic Medicine has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) for a maximum of 26 European CME Credits (ECMECs).
Teaching Faculty
William Alazawi
Queen Mary University of London
London, UK
Britta George
University hospital Zurich
Zurich CH
Charalambos Antoniades
University of Oxford
Oxford, UK
Roy S. Gardner
Golden Jubilee National Hospital
Clydebank/Glasgow, UK
Aigul Baltabaeva
Royal Brompton & Harefield Hospitals
London, UK
Christoph Gräni
Inselspital
Bern, CH
Mahmoud Barbir
Royal Brompton & Harefield Hospitals
London, UK
Tomasz Guzik
University of Edinburgh
Edinburgh, UK
Hans-Jürg Beer
Cantonal hospital Baden
Baden, CH
Shouvik Haldar
Royal Brompton & Harefield Hospitals
London, UK
Stefan Bornstein
University hospital Dresden
Dresden, DE
Adrian Heald
University of Manchester
Manchester, UK
Kate Bramham
King’s College London
London, UK
Christian Heiss
University of Surrey
Guildford, UK
Robert Byrne
Mater Private Network Dublin Hospital
Dublin, IE
Stephan Jacob
Practice for prevention and therapy
Villingen-Schwenningen, DE
A. John Camm
St. George’s University Hospital
London, UK
Pardeep Jhund
University of Glasgow
Glasgow, UK
John Chapman
Hôpital de la Pitié
Paris, FR
Paul Kalra
Portsmouth Hospitals NHS Trust
Portsmouth, UK
Derek Connolly
Birmingham City & Sandwell Hospitals
Birmingham, UK
Vikas Kapil
Queen Mary University of London
London, UK
John E. Deanfield
University College London
London, UK
Rajdeep Khattar
Royal Brompton & Harefield Hospitals
London, UK
Marc Donath
University hospital Basel
Basel, CH
Kamlesh Khunti
University of Leicester
Leicester, UK
João Pedro Ferreira
University of Porto
Porto, PT
Andrew Krentz
King’s College London
London, UK
Michael Lean
University of Glasgow
Glasgow, UK
Francesco Rubino
King’s College London
London UK
Thomas F. Lüscher
Royal Brompton & Harefield Hospitals
London, UK
Naveed Sattar
University of Glasgow
Glasgow, UK
François Mach
University hospital Geneva,
Geneva, CH
Joanne Senior
Royal Brompton & Harefield Hospitals
Harefield, UK
Theresa McDonagh
King’s College Hospital
London, UK
Michele Senni
ASST Papa Giovanni XXIII Hospital
Bergamo, IT
Kevin Moore
University College London
London, UK
Rakesh Sharma
Royal Brompton & Harefield Hospitals
London, UK
Barbara McGowan
Guy's and St Thomas' NHS Foundation Trust
London, UK
Thimoteus Speer
Goethe- University
Frankfurt am Main, DE
Geltrude Mingrone
King's College London
London, UK
Lale Tokgözoğlu
Hacettepe University
Ankara, TR
Dirk Müller-Wieland
University hospital Aachen
Aachen, DE
Frank L.J. Visseren
Utrecht Medical Center
Utrecht, NL
Philip Newsome
University of Birmingham
Birmingham, UK
Christoph Wanner
University hospital Würzburg
Würzburg, DE
Børge Nordestgaard
Copenhagen University Hospital
Copenhagen, DK
Christian Weber
Ludwig-Maximilians-University Munich
Munich, DE
Michael Papadakis
St. George’s University Hospitals
London, UK
Ashutosh Wechalekar
Royal Free Hospital
London, UK
Bertram Pitt
University of Michigan
Ann Arbor, US
David C. Wheeler
University College London
London, UK
Alison Pottle
Royal Brompton & Harefield Hospitals
Harefield, UK
Eleanor Wicks
University of Oxford
Oxford, UK
Kausik Ray
Imperial College London
London, UK
Sponsors
This meeting has been sponsored by AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo UK, Novartis, Novo Nordisk, Linc Medical and Pfizer. These companies have had no input or influence on the agenda, content of this meeting including the selection of speakers.
Under the Auspices of
In collaboration with
Anmeldeschluss